In order to further standardize and guide the clinical trials of drugs for the treatment of acute non-variceal upper gastrointestinal bleeding and provide technical specifications that can be referred to, the Center for Drug Evaluation has organized to develop the Technical Guidance for Clinical Trials of In order to standardize the research and development of low molecular weight heparin products and promote the study and evaluation of the chemical generic drugs for injection, the CDE has organized to develop the Guidance for Immunogenicity Study of Generic Drugs of Low Molecular Weight Heparin (interim) under the deployment of the NMPA, which Drugs for the Treatment of Acute NonVariceal Upper Gastrointestinal Bleeding under the deployment of the National Medical Products Administration, which was issued and implemented on August 6, 2021 upon the review and approval of the NMPA.

　　(August 06, 2021)